Navigation Links
Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
Date:4/18/2008

Trial Marks Third Study in Company's STEALTH C Clinical Program to Evaluate

Nitazoxanide in the Treatment of Chronic Hepatitis C

TAMPA, Fla., April 18 /PRNewswire/ -- Romark Laboratories, a privately held biopharmaceutical company, today announced that it has begun enrolling patients in a U.S. clinical trial to evaluate nitazoxanide for the treatment of chronic hepatitis C. Preliminary data from the study is expected in the second half of 2008.

The study, STEALTH C-3 (Studies to Evaluate Alinia for Treatment of Hepatitis C), is a Phase II randomized, double-blind, placebo-controlled clinical trial designed to evaluate the safety and efficacy of nitazoxanide in combination with peginterferon alpha-2a (Pegasys(R), Roche) and ribavirin (Copegus(R), Roche) in treatment naive patients with chronic hepatitis C infected with genotype 1.

The primary objective of STEALTH C-3 is to evaluate sustained virologic response (SVR) with a treatment regimen of 4 weeks of nitazoxanide lead-in therapy followed by 48 weeks of standard of care plus nitazoxanide versus 4 weeks of placebo lead-in followed by 48 weeks of standard of care and placebo. The trial will enroll 60 patients at 15 centers in the U.S.

"Earlier clinical studies in patients with chronic hepatitis C infected with genotype 4 have shown that nitazoxanide improves virologic response rates when used in combination with standard of care," said Dr. Emmet B. Keeffe, Chief Medical Officer of Romark. "This study and our ongoing STEALTH C-2 trial, are designed to evaluate the effect of treatment with nitazoxanide plus standard of care in patients with genotype 1. Future clinical trials will explore new combinations and treatment durations, including current and emerging HCV therapies."

STEALTH C Clinical Development Program

STEALTH C-3 is the latest in a series of clinical trials aimed at gaining a broad understanding of how nitazoxanide may benefit patients with chronic hepatitis C genotype 1 when used in combination with peginterferon and ribavirin. Other studies in the STEALTH C program include the following:

-- STEALTH C-2, a randomized, double-blind, placebo-controlled trial

currently enrolling up to 60 patients in the U.S. with chronic

hepatitis C genotype 1 who have previously failed to respond to the

standard of care with peginterferon and ribavirin. This trial is

designed to evaluate the effectiveness and safety of nitazoxanide

administered 500 mg twice daily for 4 weeks followed by nitazoxanide

plus standard of care for 48 weeks compared to placebo for 4 weeks

followed by standard of care plus placebo for 48 weeks.

-- STEALTH C-1, an international study in 120 treatment-naive and

interferon-experienced patients with chronic hepatitis C genotype 4.

Interim results from the randomized controlled Phase II clinical trial

were presented at the 58th Annual Meeting of the American Association

for the Study of Liver Diseases (AASLD) in Boston, MA and demonstrated

that 79 percent of interferon-naive patients with chronic hepatitis C

genotype 4 receiving nitazoxanide plus the standard of care had a

sustained viral response (SVR) at 12 weeks following treatment,

compared to 43 percent of patients receiving the standard of care

without nitazoxanide. The patients treated with nitazoxanide also

experienced no relapse and no more side effects than patients who

received the standard of care. Final study results (SVR-24) will be

presented at the European Association for the Study of the Liver

(EASL) in April 2008.

To learn more about Romark clinical trials currently under way, or to find out if a study is recruiting patients in your area, please visit http://www.romarktrials.com, or http://www.clinicaltrials.gov (for the latter, enter the search terms "nitazoxanide hepatitis United States.")

About Hepatitis C

Hepatitis C is a blood-borne infectious disease that is caused by the hepatitis C virus (HCV). It is the most common cause of chronic hepatitis in the U.S. and may eventually lead to cirrhosis, liver cancer and liver failure. The disease is transmitted by contact with HCV-infected blood. A large majority of those infected do not show symptoms, but fatigue, abdominal pain and nausea can be common. The current standard treatment of care, peginterferon and ribavirin, is effective in about half of all patients treated. According to the Centers for Disease Control, HCV affects an estimated 4.1 million Americans.

About Romark Laboratories

Romark Laboratories (http://www.romark.com), a privately held biopharmaceutical company, has discovered and developed a new class of small molecule antivirals known as thiazolides. The Company is developing nitazoxanide, the first of the thiazolide class, for the treatment of chronic hepatitis C, and is developing other new thiazolides for treating viral diseases including chronic hepatitis B. Alinia(R) (nitazoxanide) is approved by the U.S. Food and Drug Administration and marketed by Romark for the treatment of infections caused by Cryptosporidium or Giardia.


'/>"/>
SOURCE Romark Laboratories
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Romark Laboratories Raises $18 Million in Institutional Financing
2. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
3. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
4. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
5. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
6. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
7. BrainCells Inc. Initiates Phase 2 Clinical Trial with BCI-540 for Depression with Anxiety
8. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)
9. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
10. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
11. Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... held the largest share in the ECG Cables And ... demand for remote monitoring ECG devices. On the other hand, ... to witness the highest growth rate during the forecast period. ... Dickinson and Company (U.S.), Medtronic plc ( Ireland ... and Mindray Medical International Limited ( China ), ...
(Date:12/2/2016)... , Dec 2, 2016 Research and Markets ... Share, Development, Growth and Demand Forecast to 2022" report to their ... , , ... $6 billion in 2015, and it is expected to grow at a ... is expected to witness faster growth during the forecast period, a CAGR ...
(Date:12/2/2016)... SAN FRANCISCO , Dec. 2, 2016  PipelineRx, ... clinical telepharmacy, will be offering demonstrations of its ... American Society of Health-System Pharmacists 2016 Midyear Clinical ... Las Vegas . With nearly 300 hospital ... telepharmacy services and technology designed to dramatically improve ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... 2016 , ... On Dec. 2, 2016, CURE® magazine will host the 4th ... 2016 MPN Heroes—eight individuals who have made a difference in the field of rare ... of care, demonstrating leadership within the MPN community and/or a commitment to individual patients. ...
(Date:12/2/2016)... ... , ... Advanced Inc., a leading provider of travel therapy and travel nursing ... as Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. Jason previously served as ... operational leadership experience to Advanced Inc. He began his career in finance at Ernst ...
(Date:12/2/2016)... ... December 02, 2016 , ... The annual time frame to change ... Election Period), is ending December 7th. Currently-enrolled Medicare beneficiaries who are looking to switch ... plan (Part D) need to make changes during this period order for their new ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet’s newest campaign, ... standing as living proof that attitude and determination can combine into the most ... spike around the holidays. This campaign will offer patients a new-found hope, by ...
(Date:12/2/2016)... ... 2016 , ... Mediaplanet is proud to announce the launch ... innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping patients and physicians ... years in the last 3 decades,” says Dr. Valentine Fuster, a world-renowned cardiologist. ...
Breaking Medicine News(10 mins):